ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $38.67 Consensus Target Price from Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $38.67.

Several equities research analysts have recently issued reports on the stock. JMP Securities assumed coverage on shares of ABIVAX Société Anonyme in a research report on Wednesday, December 4th. They set an “outperform” rating and a $33.00 price objective for the company. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its stake in ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after purchasing an additional 119,300 shares during the period. abrdn plc increased its position in ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after acquiring an additional 198,225 shares during the period. Walleye Capital LLC raised its stake in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Down 0.4 %

Shares of NASDAQ:ABVX opened at $7.29 on Friday. ABIVAX Société Anonyme has a fifty-two week low of $6.53 and a fifty-two week high of $17.02. The firm’s 50 day moving average price is $8.87 and its 200 day moving average price is $10.76.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.